Study of T Lymphocytes in Patients With Horton Disease

  • End date
    Nov 23, 2022
  • participants needed
  • sponsor
    Centre Hospitalier Universitaire Dijon
Updated on 23 January 2021
steroid therapy
corticosteroid therapy
inflammatory disease
erythrocyte sedimentation rate
horton syndrome
artery biopsy
temporal artery biopsy
granulomatous inflammation


Giant-cell arteritis (GCA) is the most frequent vasculitis after 50 years. Corticosteroid therapy is the reference treatment for GCA. This treatment is highly effective but must be maintained for 12 to 24 months to avoid relapses, which causes the onset of numerous adverse effects in this elderly population.

Currently clinicians have no way to estimate this risk of relapse during the treatment of GCA.

Invariant T lymphocytes associated with the mucous membrane (MAIT), whose role in vasculitides has recently been shown and which produce IL-17 and IFN-, two key cytokines in the pathophysiology of GCA could be implicated in the pathophysiology of GCA and could constitute a predictive marker of relapse.

Our hypothesis is that blood MAIT are recruited in the artery wall in patients with GCA and that the number of circulating MAIT in the blood falls and then returns to normal if the corticoids are effective.

Given that it will be necessary to include a large number of patients to show that the persistence of a low number of circulating MAIT in patients treated with corticoids is a predictor of relapse, we propose, as the first step, to carry out a pilot study to obtain preliminary data on these new markers.

The study is classified as interventional because a lot of blood samples are taken

Condition Giant Cell Arteritis
Treatment blood samples
Clinical Study IdentifierNCT03313102
SponsorCentre Hospitalier Universitaire Dijon
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Patients who have provided written consent
Patients with national health insurance cover
Age > 50 years
Patients with Horton disease at the diagnosis, before any treatment
Horton disease is defined by ACR criteria [7], the diagnosis is made in the
presence of 3 of the following 5 criteria
Age at the onset of the disease of 50 years or older
Recent-onset localized headache
Temporal artery tenderness or decreased temporal artery pulse
Erythrocyte sedimentation rate (ESR) greater than 50 mm in the first hour (or CRP>20 mg/L)
Positive temporal artery biopsy (TAB) showing vasculitis with infiltration of mononuclear cells or granulomatous inflammation with or without giant cells
Control groups
Control Group 1: Healthy subjects Healthy subjects will be matched for age and
sex with patients. They will be recruited in Dijon only. They will be healthy
volunteers recruited among blood donors, voluntary hospital personnel (nurses
doctors and secretaries) and patients without an infectious or inflammatory
disease, or cancer or auto-immune disease (CRP<5mg/L) recruited in the
departments of investigators at the CHU of Dijon Burgundy
Control Group 2: (PPR without ACG)
Patient with oral consent
Patient affiliated to a social security system
Age > 50 years old
Patient with PPR at diagnosis, before corticosteroid treatment
No ACG (see protocol definition)
Control Group 3: (active infection)
Patient with oral consent
Patient affiliated to a social security system
Age > 50 years old
Inflammatory syndrome (CRP > 10 mg/L and fibrinogen> 4 g/L or CRP > 10 mg/L and VS > 30 mm/h) explained by a infectious syndrome defined by the association
a fever 38C, hypothermia < 35C or fever reported by the patient within 72 hours before inclusion
at least 1 associated clinical and/or radiological sign to an organ infection, for example: pneumopathy, urinary infection, bacterial dermohypodermatitis, infection digestive (non-exhasutive list)
in the absence of an explanation of the inflammatory syndrome by another cause such as an inflammatory disease or evolutive neoplastic

Exclusion Criteria

Adults under guardianship
Pregnant or breast-feeding women
Patients who have been treated with corticosteroids or immunosuppressants in the month preceding inclusion
Patients treated with chemotherapy, immunosuppressants or biotherapy
Contra-indication for corticosteroid therapy
Weight <41 kg or Hg <7g/l
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note